Introduction
Serratia marcescens, a species of Gram-negative bacillus of the Enterobacteriaceae, 1 is distributed widely in the hospital environment and has been recognized as an opportunistic pathogen causing a variety of nosocomial infections, including wound infections, 2, 3 urinary tract infections, 3, 4 pneumonia, 3 bacteremia, 3, 5, 6 endocarditis, 7 and myocarditis. 8 However, it is a rare pathogen of central nervous system (CNS) infections. There were only case reports in patients with a history of head trauma, neurosurgical procedures, mastoiditis or chronic sinusitis. 9e13 Prosthetic devices, including external cerebrospinal fluid (CSF) drainage catheters 14 and ventriculoperitoneal (VP) shunts, 11, 15 facilitate bacterial colonization and provide a potential route into the CNS, eventually causing meningitis. The use of external ventricular drains (EVDs) or VP shunts might develop an environment associated with a relatively high risk for postneurosurgical CNS infections.
In a previous study regarding post-neurosurgical meningitis, S marcescens was the most common Gram-negative pathogen, accounting nearly 10% of the total 69 identified isolates. 16 However, the literature concerning the risk factors, impacts of antimicrobial therapy and clinical outcomes for S marcescens meningitis were limited. Hence, we conducted this retrospective study to investigate the epidemiology, prognostic factors, and treatment outcomes of S marcescens meningitis.
Materials and methods

Study design, patients and case definition
This retrospective study was conducted at the Chang Gung Memorial Hospital-Linkou, a 3715-bed university-affiliated hospital and tertiary referral medical center in northern Taiwan. This study has been approved by the Institutional Research Board of CGMH-Linkou (Number: 101-0477B). Through the computer-assisted microbiology databases, all patients with CSF cultures positive for S marcescens between January 2000 and June 2011 were reviewed.
The diagnostic criteria for S marcescens meningitis were based on the isolation of S marcescens from !1 CSF cultures with at least one of the following findings consistent with meningitis: (1) clinical manifestations, such as fever, seizure, altered consciousness, or signs of meningeal irritation; and (2) laboratory evidence, including a decreased CSF glucose concentration (CSF/serum glucose ratio 0.4 or CSF glucose <40 mg/dL if serum glucose was not available), increased lactate (>36 mg/dL) and protein (>32 mg/ dL) concentrations, and pleocytosis (! 10 white blood cell/ mL) with neutrophil predominance. 16e18 Patients were excluded if S marcescens was isolated from a CSF culture without any clinical feature consistent with meningitis, or without clinical deterioration in the absence of appropriate antibiotic treatment for 3 days or more. 19 "Recurrence" was defined as a second or further meningitis episodes due to a different bacterial pathogen after the completion of therapy for the initial episode, or due to S marcescens 3 weeks or more after the completion of therapy for the first episode. "Relapse" of meningitis was considered if it was also caused by S marcescens within 3 weeks of the completion of therapy for the initial episode. 16, 20 Descriptive epidemiology Data collected from the enrolled patients included demographics, comorbid illnesses, clinical presentations and diagnoses, neurosurgeries in recent 3 months, laboratory data, severity of illness [Glasgow Coma Scale (GCS) score and Sequential Organ Failure Assessment (SOFA) score], 21 treatment courses and outcomes. Comorbid illnesses included diabetes mellitus, hepatic dysfunction (defined as the serum total bilirubin level !2.0 mg/dL or liver cirrhosis), renal insufficiency (defined as a serum creatinine level !2.0 mg/dL or a requirement of hemodialysis), chronic lung diseases, heart failure, and hematologic or solid organ malignancies.
Microbiologic analysis
Blood cultures were processed in the clinical microbiology laboratory, using the BACTEC 9240 blood culture system (Becton Dickinson Diagnostic Instrument System, USA). S marcescens isolates were identified on the basis of the following properties: aerobic, Gram-negative bacilli on a Gram's stain with an indole-negative, lysine decarboxylasepositive, and ornithine decarboxylase-positive reaction.
1 Its fermentation reactions in commercial identification system were acid produced from sucrose and D-sorbital, but not from arabinose, L-rhamnose, D-xylose, cellobiose, and D-arabitol. 1 Antimicrobial susceptibility testing was performed using the disk diffusion method according to Clinical and Laboratory Standards Institute criteria. 22 
Treatment and outcomes
Appropriate antibiotic treatment was defined as the use of one or more antimicrobial agents proved to be active against S marcescens in vitro and capable of passing through the blood-brain barrier in adequate concentrations. 14, 19 The predominant antibiotic regimen was defined as the antibiotic used for at least two-thirds of the patient's treatment course.
14 Clinical outcomes were determined by the GCS change and mortality. A favorable outcome was considered if the GCS score was unchanged or increased at the treatment endpoint, while an unfavorable outcome was considered if there was a decreased GCS score at the treatment endpoint. Treatment endpoint was the timing of discontinuation of therapy for S marcescens meningitis. We defined the mortality attributable to meningitis if the patient's death was due to the meningitis or its complications. 19 Microbiologic outcomes were determined by the interval to CSF sterilization and the recurrence or relapse of S marcescens meningitis.
Statistical analysis
Statistical analyses were done using IBM Statistical Package for the Social Sciences version 18.0 (SPSS Inc, Somers, NY, USA). Univariate analyses were performed with the chisquare test or Fisher's exact test for categorical variables, and the Student's t test or Wilcoxon test for continuous variables, as appropriate. Odds ratio (OR) and 95% confidence interval (CI) were calculated to evaluate the strength of any associations as well as the precision of the estimate of effect in the outcome analyses. Variables with a two-tailed p value <0.05 were entered to a backward multivariate logistic regression model to determine the factors independently associated with unfavorable outcome. A two-tailed p value <0.05 was considered statistically significant.
Results
Descriptive epidemiology
During the 10-year period of the study, 34 patients had S marcescens isolated from at least one CSF specimens. Of the 34 patients identified, 33 met the diagnostic criteria and one was contaminant. Of the 33 enrolled patients, 20 were males and 13 were females, with a mean age of 49.6 years (range, 1 month to 86 years old). Of them, 6 (18.2%) did not have any comorbid illness. The first three most common comorbid illnesses were benign or malignant brain tumors (18 patients, 54.5%), followed by diabetes mellitus (five, 15.2%) and chronic lung diseases (three, 9.1%). Only one patient did not receive neurosurgical intervention before the onset of meningitis. Patients' demographics, associated neurosurgical conditions, and comorbid illnesses are listed in Table 1 . The most common neurosurgical conditions were benign or malignant brain tumors (16, 50.0%), followed by hemorrhagic cerebrovascular accidents (five, 15.6%).
The mean interval between the first neurosurgical procedure and the diagnosis of meningitis was 17.1 days (range, 4e51 days). The mean time from the diagnosis of S marcescens meningitis to adequate treatment was 2.8 days (range, 0e27 days), and 18 patients (54.5%) received appropriate antimicrobial therapy within 48 hours of the diagnosis of S marcescens meningitis. Twenty-eight patients had two or more additional CSF cultures performed after the diagnosis of S marcescens meningitis, and the mean interval to CSF sterilization was 15.2 days (range, 3e43 days). In this study, 20 patients (60.6%) had a favorable outcome, while 13 (39.4%) had an unfavorable outcome. Overall, five patients (15.2%) died in the hospital; one died of meningitis, and the other four died of their comorbidities (e.g., nosocomial pneumonia) or the underlying neurosurgical conditions (e.g., intracranial malignancy) despite CSF sterilization from meningitis.
Clinical and laboratory characteristics of S marcescens meningitis
The clinical features, laboratory data and outcomes of S marcescens meningitis are summarized in Table 2 . Two major initial clinical manifestations were fever (30 patients, 90.9%) and altered consciousness (20, 60.6%) . CSF abnormalities at the onset of S marcescens meningitis included pleocytosis (mean, 6510 cells/mL, with 75% polymorphonuclear leukocytes), decreased CSF glucose concentration (mean, 36.8 mg/dL), elevated CSF protein concentration (mean, 534.6 mg/dL), and elevated CSF lactate concentration (mean, 107.2 mg/dL). Twenty-one patients (84.0%) had a positive Gram's staining, and two (6.1%) had polymicrobial infections, including one co-infected with Pseudomonas aeruginosa and the other co-infected with Acinetobacter baumannii. There were five patients with concomitant S marcescens bacteremia, two with concurrent pneumonia, and two with intra-abdominal infections. The average scores of GCS and SOFA were 13.3 and 3.5 at the diagnosis of meningitis, respectively. The overall all-cause mortality of patients in this study was 15.2% (5/33).
Twenty-eight patients had brain CT scans or magnetic resonance imaging48 hours before or after the diagnosis of S marcescens meningitis, and two of them had negative findings. Positive image findings were as follows: hydrocephalus (18, 64.3%), midline shift (10, 35.7%), brain abscess (5, 17.9%), infarction (4, 14.3%), and leptomeningeal enhancement (1, 3.6%).
Risk factors for unfavorable outcomes
All the 33 enrolled patients had a GCS score >3 at the onset of S marcescens meningitis. The analysis of potential risk factors for unfavorable outcome is listed in Table 3 . According to the univariate analysis, benign or malignant brain tumors, twofold elevation of CSF lactate concentration above upper limit of normal (ULN), higher serum C-reactive protein (CRP) levels (>5 mg/L), more ICU stays, and higher SOFA score at the onset of S marcescens meningitis were significantly associated with unfavorable outcomes. Diabetic patients had the trend towards unfavorable outcomes, but the difference was not statistically significant.
Variables in multivariate analysis included benign or malignant brain tumors, CSF lactate !2x ULN, and SOFA score at the onset of S marcescens meningitis. After analysis of aforementioned variables, CSF lactate !2x ULN (odds ratio, 7.20; 95% CI, 1.08e47.96; p Z 0.041) was independently associated with unfavorable outcomes for patients with S marcescens meningitis.
Antimicrobial therapy and outcomes
There were two patients with recurrence of meningitis, and no patient had relapsed S marcescens meningitis. The first patient was a 1-month-old premature female infant with spontaneous S marcescens meningitis and initially presenting fever and seizure. Her computed tomography (CT) revealed hydrocephalus and ventriculitis. She received patent ductus arteriosus ligation 18 days before the episode of S marcescens meningitis. Third-generation cephalosporins were administered intravenously 48 hours after the onset of meningitis, and had been used for 52 days in total. CSF sterilization was achieved 7 days after initiation of treatment. EVD was also performed for increased intracranial pressure. However, infection recurred 2 weeks after the completion of therapy for the initial episode, and the recurrent meningitis was caused by Klebsiella oxytoca. Another course of antibiotic therapy with third-generation cephalosporins was initiated, and she recovered from the recurrent meningitis.
The second patient with recurrence of S marcescens meningitis was a 45-year-old male receiving craniectomy for removal of brain trigeminal schwannoma 8 days before the onset of S marcescens meningitis. Initial presentations were fever and altered consciousness. Treatment with intravenous third-generation cephalosporin lasted for 46 days, and he also had the surgical debridement and EVD revisions twice. CSF sterilization was achieved 16 days after diagnosis. He had S marcescens CNS infection again around 2.5 months after the completion of therapy for the first episode. His second episode was presented as an epidural abscess. He was retreated with surgical debridement and third-generation cephalosporin, which resulted in a favorable outcome.
Of the 33 patients enrolled, only one third-generation cephalosporin-resistant S marcescens isolate was recovered, which was collected from subdural empyema occurring 2 months after initial craniotomy. All patients received appropriate intravenous antibiotic treatment and none of them was treated with intrathecal antibiotics. Twentyseven patients (81.8%) received monotherapy with thirdgeneration cephalosporins, while six patients (18.2%) received meropenem or imipenem. No seizures were observed in any of the patients who received carbapenem therapy.
Carbapenems and third-generation cephalosporins, such as ceftriaxone, ceftazidime and flomoxef, were the most frequently used antibiotics. Patients treated with thirdgeneration cephalosporins had a shorter mean time to CSF sterilization than carbapenems (14 vs. 33 days, p Z 0.021), but the duration of therapy, unfavorable outcome, and mortality had no statistical difference between these two different classes of antimicrobial agents (Table 4) .
Discussion
To the best of our knowledge, this is the largest study regarding S marcescens meningitis in the English literature. In this study, cases occurred sporadically over a 10-year period, and all the enrolled patients were hospitalized at different wards or ICUs, so outbreak of S marcescens meningitis was not likely. Most of the patients in this study had neurosurgical intervention, accounting for 97.0% (32/33) of total cases. Compared with other Gram-negative meningitis, S. marcescens meningitis occurred more frequently in post-neurosurgical patients Data presented as n (%) or mean AE standard deviation. GCS Z Glasgow Coma Scale; SOFA Z Sequential Organ Failure Assessment.
(97.0% vs. 33.3e84.6%). 23e36 This result may alert neurosurgeons the bacteriology of postneurosurgical bacterial meningitis. These CNS infections due to S marcescens had quite variable clinical presentations ranging from surgical wound or ventricular shunt infections to deeply localized abscess formation in brain parenchyma, epidural space, or bone-flap.
The second characteristic finding distinguishing our study from previous studies for Gram-negative meningitis is the higher percentage of benign or malignant brain tumor (54.5% versus 0e26.7%). 23e26 The relationship between S marcescens infections and malignancy has been reported by Haddy et al. 27 They presented a study of S marcescens Patients' GCS scores are the important prognostic variables for bacterial meningitis. 14, 28 The comparison of GCS change between the onset of S marcescens meningitis and at the end of treatment for meningitis could be more practical for physicians to predict the prognosis. CSF lactate is a good indicator in clinical practice to distinguish bacterial meningitis from aseptic meningitis in combination with other CSF characteristics. 18, 29, 30 It is also a quick, sensitive, and specific test to identify patients with postneurosurgical bacterial meningitis. 31 Besides, from a meta-analysis of 25 previous studies, its diagnostic accuracy was higher than that of conventional markers (i.e., CSF Gram's stain, CSF leukocyte counts, CSF glucose, CSF/plasma glucose ratio, and CSF protein). 30 The role of CSF lactate level in predicting prognosis of bacterial meningitis is still conflicting. 29, 32, 33 In this study, CSF lactate level !2x ULN (cutoff, 72 mg/dL) was proved to be a valid ancillary test in predicting unfavorable outcomes for patients with S marcescens meningitis.
Recent epidemiologic data showed an increasing frequency of antimicrobial resistance among S marcescens isolates. 34e36 In this study, 32 S marcescens isolates from initial positive CSF sampling were all susceptible to ceftriaxone, ceftazidime, imipenem, amikacin, and gentamicin, and 31 of them were obtained from post-neurosurgical patients. Resistance to third-generation cephalosporins was only detected in one CSF isolate. Antibiotic therapy with or without neurosurgical intervention (i.e., shunt removal and/ or abscess drainage) was the mainstay of treatment for our patients. Compared with carbapenems, third-generation cephalosporins had a shorter mean time to CSF sterilization (14 vs. 33 days, p Z 0.021). Nevertheless, this phenomenon was not observed in patients with Enterobacter meningitis. 12 In a review of the treatment strategies for CSF shunt infections, retention of the shunt resulted in poor cure rates regardless of whether there was the use of intravenous antibiotics alone (cure rate of 24%) or with concurrent intrathecal antibiotics (cure rate 40%). In the treatment of secondary infection of an external ventricular device, removal of the device was required. 37 In this study, there was no significant difference in the outcome no matter what neurosurgeons did the removal or revision of external CSF drainage catheters or VP shunts (Table 3) .
This study has limitations for its retrospective design and the small number of patients studied. However, the infrequent nature of this infection makes prospective evaluation very difficult. In addition, although this is the largest reported series of S marcescens meningitis to date, the single-institution setting may limit the generalizability of the findings.
In conclusion, a neurosurgical procedure for brain solid tumor has the potential for the development of S marcescens meningitis. The overall mortality of S marcescens meningitis is around 15%. CSF lactate concentration !2x ULN is independently associated with an unfavorable outcome. Most of the S marcescens CSF isolates were still susceptible in vitro to third-generation cephalosporins over a 10-year period, and the empiric therapy with parenteral third-generation cephalosporins yielded satisfactory results.
